WWW - Posts tagged Cumberland Pharmaceuticals at BloggingStocks

Cumberland Pharmaceuticals posts

Closing Bell: Inflation No Threat, Retail Sales Rise, Market Inches Higher (CPIX, INTC, CSTR, SBIB, NANO)

Posted Jan 14th 2011 4:00PM by Jon Ogg (RSS feed)
Filed under: Intel (INTC), S and P 500, DJIA, NASDAQ

Government reports that the US inflation rate came in at 1.5% for 2010 (or just 0.1% excluding energy and food prices) produced little enthusiasm in the markets. Even a 0.4% increase in retail sales during the holiday season didn't give traders a push. Probably because they were expecting better. Both oil and gold prices have fallen today, and the dollar is slipping against the euro as currency traders judge that US consumers just don't have the heart to spend in a big way. US markets are closed Monday in observance of the birthday of Martin Luther King, Jr.

Here are the numbers for early afternoon trading today:

Dow Jones: 11,787.38 +55.48 (0.47%)
S&P 500: 1,293.24 +9.48 (0.74%)
Nasdaq: 2,755.30 +20.01 (0.73%)

Continue reading Closing Bell: Inflation No Threat, Retail Sales Rise, Market Inches Higher (CPIX, INTC, CSTR, SBIB, NANO)

Cumberland Pharma Plummets After FDA Rejection

Posted Dec 22nd 2010 1:00PM by Elizabeth Harrow (RSS feed)
Filed under: Major Movement, Analyst Upgrades and Downgrades, Bad News, Technical Analysis

Shares of Cumberland Pharmaceuticals (CPIX) are having a rough go of it after the Food and Drug Administration (FDA) outlined some concerns that will further delay a ruling on its liver drug. The regulatory agency already postponed its decision from August to December, and now the FDA says it needs additional data before it can recommend the drug for approval.

In its complete response letter to Cumberland, the FDA noted insufficient evidence to prove that the injectable drug, Acetadote, is effective in all patients. Cumberland said it plans to meet with the FDA soon to address the outstanding issues.

Continue reading Cumberland Pharma Plummets After FDA Rejection

Cumberland Pharmaceuticals ekes out an IPO

Posted Aug 11th 2009 3:00PM by Tom Taulli (RSS feed)
Filed under: Wells Fargo (WFC), Initial Public Offerings

It was not a good sign. Last night, Cumberland Pharmaceuticals priced its IPO at $17 a share, which was below the $19-$21 range. And, in light of this weakness, the stock is down 9 cents to $16.91 so far in today's trading.

Yet, Cumberland is a fairly solid company. Focused on specialty pharmaceuticals, it has several branded prescription products. The main target areas include: hospital acute care and gastroenterology.

A key differentiator is Cumberland's efficient direct sales model. In all, there are only 66 sales reps. Then again, because of Cumberland's laser focus, it is easier to target the market.